Zydus Cadila secures USFDA nod for Irbesartan drug

Our Bureau Updated - March 12, 2018 at 02:18 PM.

Cadila Pharmaceuticals Ltd (Zydus Cadila) on Saturday said it has received an approval from the United States Food and Drug Administration (USFDA) for Irbesartan tablets, used in the treatment of hypertension.

The approval has been given for USP 75 mg, 150 mg and 300 mg, according to a company statement here.

The estimated sales in 2011 as per NDC for Irbesartan Tablets were $489 million.

Published on September 29, 2012 11:40